Statements (49)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:health_services
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:available_in |
gptkb:United_Kingdom
gptkb:United_States |
| gptkbp:benefits |
promotes healing
|
| gptkbp:clinical_trial |
improved patient outcomes
ongoing studies demonstrated efficacy cost-effective treatment reduced healing time |
| gptkbp:clinical_use |
surgical wounds
pressure ulcers venous leg ulcers diabetic ulcers traumatic wounds |
| gptkbp:collaborates_with |
medical institutions
|
| gptkbp:competitors |
competes with other wound care products
|
| gptkbp:contains |
Regenerative tissue technology
|
| gptkbp:developed_by |
Tissue Regenix Group plc
|
| gptkbp:distribution_channels |
hospitals
clinics home healthcare providers |
| gptkbp:future_plans |
enhance research initiatives
expand product range increase market presence |
| https://www.w3.org/2000/01/rdf-schema#label |
Tissue Regenix Wound Care
|
| gptkbp:innovation |
new formulations
continuous product development enhanced delivery systems |
| gptkbp:invention |
patented technology
|
| gptkbp:marketed_as |
advanced wound care solution
|
| gptkbp:part_of |
Tissue Regenix product line
|
| gptkbp:partnerships |
industry partnerships
academic partnerships research collaborations |
| gptkbp:regulatory_compliance |
gptkb:CE_mark
MHRA approval |
| gptkbp:research_focus |
regenerative medicine
|
| gptkbp:sustainability |
biodegradable materials
environmentally friendly production |
| gptkbp:target_market |
healthcare providers
|
| gptkbp:target_patient_group |
patients with non-healing wounds
|
| gptkbp:type |
biological dressing
|
| gptkbp:used_for |
treatment of chronic wounds
|
| gptkbp:user_feedback |
positive reviews
high satisfaction rates recommended by healthcare professionals |
| gptkbp:bfsParent |
gptkb:Tissue_Regenix_Group
|
| gptkbp:bfsLayer |
6
|